CEL-SCI Announces Closing of Public Offering
21 7월 2023 - 12:36AM
Business Wire
CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American:
CVM), a Phase 3 cancer immunotherapy company, today announced the
closing of its previously announced public offering of 2,500,000
shares of its common stock at a public offering price of $2.00 per
share, for gross proceeds of $5,000,000, before deducting
underwriting discounts and offering expenses.
The Company intends to use the proceeds from the offering to
fund the continued development of Multikine* and for general
corporate purposes.
ThinkEquity acted as sole book-running manager for the
offering.
The offering is being made pursuant to an effective shelf
registration statement that has been filed with the U.S. Securities
and Exchange Commission (the “SEC”). The final prospectus
supplement relating to the offering was filed with the SEC and is
available on the SEC's website at http://www.sec.gov. Copies of the
final prospectus supplement and the accompanying prospectus
relating to the offering may be obtained from ThinkEquity, 17 State
Street, 41st Floor, New York, New York 10004, Attention: Prospectus
Department.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such state or other jurisdiction.
About CEL-SCI Corporation
CEL-SCI is a clinical-stage biotechnology company focused on
finding the best way to activate the immune system to fight cancer
and infectious diseases. The Company’s lead investigational therapy
Multikine completed a pivotal Phase 3 clinical trial involving head
and neck cancer, for which the Company has received Orphan Drug
Status from the FDA. The Company has operations in Vienna,
Virginia, and near Baltimore, Maryland.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. When used in this press release, the words "intends,"
"believes," "anticipated," "plans" and "expects," and similar
expressions, are intended to identify forward-looking statements.
Such statements are subject to risks and uncertainties that could
cause actual results to differ materially from those projected.
Such statements include, but are not limited to, statements about
the offering. Factors that could cause or contribute to such
differences include an inability to duplicate the clinical results
demonstrated in clinical studies, timely development of any
potential products that can be shown to be safe and effective,
receiving necessary regulatory approvals, difficulties in
manufacturing any of the Company's potential products, inability to
raise the necessary capital and the risk factors set forth from
time to time in CEL-SCI's filings with the Securities and Exchange
Commission, including but not limited to its report on Form 10-K
for the year ended September 30, 2022. The Company undertakes no
obligation to publicly release the result of any revision to these
forward-looking statements which may be made to reflect the events
or circumstances after the date hereof or to reflect the occurrence
of unanticipated events.
* Multikine (Leukocyte Interleukin, Injection) is the trademark
that CEL-SCI has registered for this investigational therapy. This
proprietary name is subject to FDA review in connection with the
Company's future anticipated regulatory submission for approval.
Multikine has not been licensed or approved for sale, barter or
exchange by the FDA or any other regulatory agency. Similarly, its
safety or efficacy has not been established for any use.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230719417414/en/
Gavin de Windt CEL-SCI Corporation (703) 506-9460
www.cel-sci.com
Cel Sci (AMEX:CVM)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Cel Sci (AMEX:CVM)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024